If downregulation of CD88 is known to be associated with injury severity and is increased in neutrophils after semaglutide treatment, our results also suggest an anti-inflammatory benefit of this drug in patients with obesity and CVD. This evidence concerns the gene C5AR1 and obesity disorder.